baber/WOPTO huggingface dataset:
Patent EP-3641860-A1 (EP)
Inventor: STEWART JUSTIN
IPC: A61M5/32
Filed: 2018-06-11
Abstract: A needle shield remover for assembly with a cap of a medicament delivery device, wherein the needle shield remover comprises a longitudinally elongated tubular body (10, 10', 10'') having a plurality of structural features, wherein said plurality of structural features are symmetrically disposed on the tubular body (10, 10', 10''), in relation to a plane of symmetry which is perpendicular to a longitudinal axis.
Patent EP-3609899-A1 (EP)
Inventor: LONG DANIEL D
IPC: C07H15/26
Filed: 2018-05-22
Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula (I), where W 1 , R 1  and A 1  are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
Patent EP-3631018-A1 (EP)
Inventor: SCAFE CHARLES
IPC: C12Q1/6886
Filed: 2018-05-25
Abstract: A method for detecting large rearrangements in BRCA1 and BRCA2 genes includes amplifying a nucleic acid sample in the presence of a primer pool to produce amplicons, where the primer pool includes target specific primers targeting regions of exons of the BRCA1 and BRCA2 genes. The method further includes sequencing the amplicons to generate a plurality of reads, mapping the reads to a reference sequence, determining a number of reads per amplicon for the amplicons associated with the exons of the BRCA and the BRCA2 genes, determining exon copy numbers for the exons of the BRCA1 and BRCA2 genes based on the number of reads per amplicon, detecting an exon deletion or duplication based on the exon copy numbers, and detecting a whole gene deletion of the BRCA1 or BRCA2 gene based on the number of reads per amplicon associated with the exons of the BRCA1 and BRCA2 genes.
Patent EP-3649789-A1 (EP)
Title: Portioned video streaming concepts
Inventor: SKUPIN ROBERT
IPC: H04N21/2347
Filed: 2018-07-06
Abstract: Portion- or tile-based video streaming concepts are decribed.
Patent EP-3631680-A1 (EP)
Inventor: BERLUSCONI DAVIDE LUIGI
IPC: E05G5/00
Filed: 2018-05-31
Abstract: A system for generation of a virtual template of at least one part of the body of a user, comprising at least one acquisition unit (1), which acquisition unit (1) consists of a structure defining an acquisition chamber (11), which structure comprises a plurality of image capture devices (12) such as cameras or the like. Said structure consists of a frame for supporting a plurality of panels (13), each panel (13) having arranged thereon a corresponding image capture device (12) facing said acquisition chamber (11), the panels (13) being arranged in such a way that said acquisition chamber (11) is shaped as an egg.
Patent EP-3649313-A1 (EP)
Inventor: SOBOLEWSKI UWE
IPC: E05F1/12
Filed: 2018-06-26
Abstract: The invention relates to a shutter fitting (4), in particular for a piece of furniture, said fitting comprising a housing (5) which can be fixed to a body (2), on which housing a supporting arm (6) is mounted rotatably, and comprising a pivotably mounted control arm (7), wherein the supporting arm (6) and the control arm (7) can be hingedly connected to a shutter (3) at an attachment point (9) via spaced-apart axes of rotation (61, 71), wherein a damper (96) is provided at the attachment point (9) and can be actuated via a movement of the supporting arm (6) and/or the control arm (7) in the event of an opening movement of the shutter (3), before the maximum opening position is reached. The handling of the shutter fitting during the opening process is thus improved.
Patent EP-3629944-A1 (EP)
Inventor: COSTANTINI RAFFAELE
IPC: A61B17/28
Filed: 2018-05-09
Abstract: Multifunctional surgical instrument for extension of laparotomic, laparoscopic, robotic and thoracotomic incisions, allowing at the same time the spreading apart of the cutaneous/subcutaneous corners, pinching and lifting of the deep parietal layer, its dissection with the electrosurgical knife and protection of the surrounding and underlying tissues, particularly the intestinal ansae in the peritoneal cavity, during the dissection itself. The instrument comprises a handle with two rings, upper and lower, two straigth branches, upper and lower, and a toothed racked stopper, after connecting through a hub the two branches extend to constitute the two prongs of the bite, the lower straight branch extends to constitute the upper prong which after an angle of approximately 130 degrees becomes shaped as an L ribbon- like retractor, centrally fenestrated with a paddle angulated at 90 degrees, facing upwards, terminating at the top with an outwards angulation, the upper straight branch extends to constitute the lower prong of the bite which, too, after an angle of approximately 130 degrees at the same level as the angle of the upper prong, becomes shaped as a curved concave valve, with all the components of the surgical instrument situated distally to the upper third of the straight branches of the handle being covered with proper electrical insulated coating.
Patent EP-3649259-A1 (EP)
Title: Target-enriched multiplexed parallel analysis for assessment of risk for genetic conditions
Inventor: KOUMBARIS GEORGE
IPC: C12Q1/6883
Filed: 2018-07-06
Abstract: The invention provides methods for assessment of risk for genetic conditions using target-enriched multiplexed parallel analysis, for example fetal risk for genetic conditions in prenatal testing. The methods of the invention utilize TArget Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods of the disclosure can be used to determine carrier status of inheritable genetic abnormalities associated with genetic conditions and from this information the fetal risk of inheriting the genetic condition can be determined. Kits for carrying out the methods of the invention are also provided.
Patent EP-3834493-A1 (EP)
Inventor: DREVON NICOLAS
IPC: H04W48/00
Filed: 2018-08-10
Abstract: A communication system includes a service responsible for sending signaling to a user equipment or an access network serving the user equipment. The service receives a request to send the signaling to the user equipment or the access network together with access type control information indicating whether the signaling is transmittable using any of a plurality of access types or a specific access type provided in the request. The service selectively forwards the signaling to the user equipment or the access network based on the access type control information.
Patent EP-3665196-A1 (EP)
Inventor: OESTERGAARD MIKKEL ZAHLE
IPC: A61K39/395
Filed: 2018-08-08
Abstract: The present invention relates to obinutuzumab (or its functional equivalents) for use in the treatment of a particular biomarker-defined DLBCL patient and a novel DLBCL patient subgroup, respectively. The present invention further relates to a method for treating DLBCL with obinutuzumab (or its functional equivalents) in a patient in need thereof, wherein said patient is a particular biomarker-defined DLBCL patient or belongs to a novel biomarker-defined DLBCL patient subgroup. The present invention further relates to the use of obinutuzumab (or its functional equivalents) for the preparation of a pharmaceutical composition for the treatment of DLBCL in the particular biomarker-defined DLBCL patient/novel DLBCL patient subgroup. The present invention further relates to a method for identifying a particular DLBCL patient/novel DLBCL patient subgroup and a method for diagnosing a novel form of DLBCL and a particular DLBCL patient/novel DLBCL patient subgroup, respectively.
Patent EP-3590509-A1 (EP)
Inventor: LIM YONG TAIK
IPC: A61K9/127
Filed: 2018-03-02
Abstract: The present invention relates to a multi-domain vesicle comprising an immunosuppressive factor control material, a production method of the multi-domain vesicle and an immunomodulatory composition comprising the multi-domain vesicle. According to one aspect of the present invention, the multi-domain vesicle comprises: at least two liposomes making contact and connected with each other, and a multi-domain vesicle outer wall surrounding the at least two liposomes. The multi-domain vesicle is formed from an oil phase and an aqueous phase, wherein: the oil phase comprises a first immunomodulatory material and a fluid oil; the oil phase forms a membrane of the liposomes, and the multi-domain vesicle outer wall; the aqueous phase comprises a second immunomodulatory material; the aqueous phase is an internal aqueous phase of the membrane of the liposomes, and an outer aqueous phase of the membrane of the liposomes; the first immunomodulatory material and the second immunomodulatory material are immunosuppressive factor control materials; and the fluid oil improves the structural stability of the at least two liposomes making contact and connected with each other.
Patent EP-3665634-A1 (EP)
Inventor: HOWARD JAMES W
IPC: G06Q30/00
Filed: 2018-08-06
Abstract: In some examples, an article may include a layer having a first surface marked with a first code. The article may include a second surface marked with a second code, the second code obscured by the layer to be unreadable through the layer. The first code and the second code may be associated in transaction data stored by a blockchain managed by a consensus network of nodes.
Patent EP-3603197-A1 (EP)
Inventor: AWADA AHMAD
IPC: H04W76/15
Filed: 2018-03-08
Abstract: According to an example aspect of the present invention, there is provided an apparatus comprising at least one processing core, at least one memory including computer program code, the at least one memory and the computer program code being configured to, with the at least one processing core, cause the apparatus a least to cause the apparatus to participate in a communication session wherein a control plane is received from at least two access nodes (510), monitor radio link quality of at least two radio links comprised in the communication session (520), and select a time duration, for determining a radio link failure of a first radio link from among the at least two radio links, wherein the selection is based at least partly on radio link quality of a second radio link from among the at least two radio links (530).
Patent EP-3608981-A1 (EP)
Inventor: ONODERA Nozomi
IPC: H01L51/30
Filed: 2018-03-19
Abstract: The purpose of the present invention is to provide an organic semiconductor composition suitable for preparing an organic thin film by a solution method, an organic thin film obtained by using the organic semiconductor composition, and a practical field effect transistor which uses the organic thin film, has small variances in mobility while maintaining a high mobility, and also has small variances in a threshold value. That is, disclosed in the present specification is an organic semiconductor composition including an organic semiconductor compound, an insulation compound, an organic solvent A which is a good solvent for the insulation compound, and an organic solvent B which is a poor solvent for the insulation compound and has a higher boiling point than the organic solvent A. The mass ratio a:b of the organic solvent A and the organic solvent B is 1:8 to 8:1.
Patent EP-3687765-A1 (EP)
Inventor: COOPER GUTHRIE
IPC: B29C64/386
Filed: 2018-08-21
Abstract: A three dimensional printing system (2) includes a plurality of light engines (4), an alignment article (40), a camera (46), and a controller (26). The plurality of light engines define a corresponding plurality of build fields which overlap and define a build plane (6). The alignment article carries an alignment calibration image and is configured to be mounted in the three dimensional printing system with the alignment calibration image (44) proximate to the build plane and in facing relation with the plurality of light engines. The alignment calibration image defines a dark field with an array of reflective alignment targets. The camera is mounted to be in facing relation to the alignment calibration image. The controller is configured to operate at least the light engines and the camera to individually align the light engines to the alignment calibration image.
Patent EP-3724006-A1 (EP)
Inventor: KRISTEN FLORIAN
IPC: B60C11/03
Filed: 2018-09-24
Abstract: Die Erfindung betrifft einen Nutzfahrzeugreifen mit einem Laufstreifen mit zumindest zwei auf Profiltiefe (T) ausgeführten Umfangsrillen (3), welche mittlere Profilpositive (1) und schulterseitige Profilpositive (2) voneinander trennen, wobei die Umfangsrillen (3) zu den mittleren Profilpositiven (1) Rillenflanken (5a, 5b) und die schulterseitigen Profilpositive (2) zur Seitenwand verlaufende Schulterflanken (6) aufweisen. Zumindest eine Rillenflanke (5a, 5b) zumindest einer Umfangsrille (3) und/oder zumindest eine Schulterflanke (6) ist mit in die Profilpositive (1, 2) hineinragenden, zur Laufstreifenoberfläche offenen Vertiefungen (7, 7') versehen, welche, jeweils an der Laufstreifenperipherie ermittelt, gegenüber dem Niveau der Rillenflanke (5 a, 5b) bzw. Schulterflanke (6) eine Tiefe (t 1 , t 1 ') von 2,0 mm bis 5,0 mm und am Niveau der Rillenflanke (5a, 5b) bzw. Schulterflanke (6) eine Breite (bi, bi ') von 4,0 mm bis 15,0 mm aufweisen, wobei jede Vertiefung (7, 7') durch zumindest eine Fläche (7c, 7d, 7'd) begrenzt ist, wobei die Fläche(n) (7c, 7d, 7'd) derart gekrümmt ist bzw. sind, dass sie an ihrem bzw. ihren radial inneren Enden in einer in radialer Richtung ermittelten Tiefe (T 1 ) von 35% bis 90% der Profiltiefe (T) knickfrei in die Rillenflanke (5a, 5b) bzw. in einer in radialer Richtung ermittelten Tiefe (T 1 ') von 35% bis 150% der Profiltiefe (T) knickfrei in die Schulterflanke (6) übergehen.
Patent EP-3685026-A1 (EP)
Inventor: HIRTH PETER
IPC: F01N5/02
Filed: 2018-09-18
Abstract: The invention relates to a catalytic converter for treating exhaust gases of an internal combustion engine, said catalytic converter comprising a housing, through which an exhaust gas can flow, having an inflow side and an outflow side, wherein a plurality of flow channels (4, 13) is formed in the housing and exhaust gas can flow through said flow channels along a main throughflow direction from the inflow side towards the outflow side, wherein at least one pipe (5, 12) through which a fluid which is independent from the exhaust gas that can flow through the flow channels (4, 13) is provided in the housing.
Patent EP-3697769-A1 (EP)
Inventor: BAATI RACHID
IPC: A61K31/4427
Filed: 2018-10-17
Abstract: The present invention relates to a compound of formula (II), as well as to a process for preparing the compounds of formula (II) by a chemoselective Sonogashira reaction. It also relates to a pharmaceutical composition comprising at least one compound of formula (II) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organophosphorous nerve agent; in the treatment of neurological diseases such as Alzheimer's disease; and/or in the treatment of cancer; and/or for use as antiviral drug.
Patent EP-3701044-A1 (EP)
Inventor: BALMFORTH BARNABY
IPC: C12Q1/6823
Filed: 2018-10-23
Abstract: L'invention concerne un procédé permettant de détecter si la base nucléique d'une molécule de nucléoside triphosphate donnée dans un analyte comprend ou non une modification chimique ou structurale donnée, caractérisé par les étapes consistant à (1) faire réagir l'analyte en présence d'une polymérase avec une sonde biologique constituée de (a) une paire de premiers oligonucléotides à simple brin comprenant chacun un site de blocage d'exonucléases ; au moins un site de reconnaissance d'endonucléases de restriction situé du côté 3' du site de blocage ; un site de capture d'un nucléotide simple situé à l'intérieur du site de reconnaissance et respectivement un ou plusieurs premiers et seconds fluorophores situés du côté 3' du site de reconnaissance conçus pour être pratiquement indétectables et (b) au moins un deuxième et éventuellement au moins un troisième oligonucléotide à simple brin chacun séparé du premier oligonucléotide et pouvant s'hybrider avec des régions flanquantes complémentaires sur les côtés 3' et 5' du site de capture de l'un ou l'autre des premiers oligonucléotides ou des deux de la paire pour créer un duplex de sondes utilisées constitué de (b1) l'un ou l'autre des premiers oligonucléotides de la paire et (b2) un composant constitué du deuxième oligonucléotide, de l'un ou l'autre d'un nucléotide modifié ou non modifié dérivé de la molécule de nucléoside triphosphate et éventuellement du troisième oligonucléotide, chaque duplex étant constitué de l'une des quatre permutations (b1)/(b2) possibles ; (2) faire réagir le duplex produit dans l'étape (1) avec un système d'endonucléases de restriction constitué d'au moins une endonucléase de restriction conçue pour couper sélectivement le brin (b1) au niveau du site de reconnaissance pour créer selon la présence ou l'absence de la modification dans la molécule de nucléoside triphosphate d'origine (i) seulement des premiers éléments oligonucléotidiques digestibles de manière exonucléolytique portant un ou plusieurs premiers fluorophores ou (ii) seulement des premiers éléments oligonucléotidiques digestibles de manière exonucléolytique portant un ou plusieurs seconds fluorophores ou (iii) un mélange de premiers éléments oligonucléotidiques digestibles de manière exonucléolytique portant respectivement un ou plusieurs premiers et seconds fluorophores ; (3) créer un autre duplex de sondes utilisées provenant du composant (b2) et d'un autre premier oligonucléotide de la paire et par la suite réitérer les étapes (2) et (3) ; (4) digérer les premiers éléments oligonucléotidiques avec une enzyme ayant une activité exonucléolytique 5'-3' pour produire un ou plusieurs fluorophores dans un état détectable après l'une ou l'autre des étapes (2) et (3) ou les deux ; et (5) détecter le ou les fluorophores libérés dans l'étape (4) et déduire de la nature du signal de fluorescence observé si la molécule de nucléoside simple triphosphate d'origine était modifiée ou non modifiée.
Patent EP-3678974-A1 (EP)
Inventor: STOOF PIETER MARIA
IPC: B66C23/76
Filed: 2018-09-07
Abstract: Provided is a crane with a main boom and a back mast, of which at least one comprises an first mast upper part comprising at least one mast section and a first mast lower part comprising at least one mast section, and a first mast tilting. The first mast tilting member is arranged between the first mast upper part and the first mast lower part, and has a straight hoisting state wherein the first mast upper part and the first mast lower part are essentially in line with each other, and a tilted hoisting state wherein the first mast upper part is tilted with respect to the first mast lower part.
Patent EP-3684902-A1 (EP)
Title: Pouched unit and method of using said pouched unit
Inventor: BOOD ARIE
IPC: B65D81/32
Filed: 2018-09-19
Abstract: A pouched unit comprising a dose of a substance which is enveloped by a main part of a pouch made from a water soluble material, wherein the pouch comprises a secondary part made from the water soluble material, the secondary part is attached to the main part via a weaker area of the water soluble material, which weaker area is configured to allow manual separation of the secondary part from the main part, and a message is provided on the secondary part.
Patent EP-3616692-A1 (EP)
Inventor: LEE KONG JOO
IPC: A61K31/085
Filed: 2018-04-30
Abstract: The present disclosure relates to a pharmaceutical composition for suppressing cancer metastasis containing, as an active ingredient, an activator compound of the cancer metastasis inhibitor Nm23, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present disclosure may suppress the metastasis of cancer cells by promoting the activity of Nm23 associated with cancer metastasis, and thus may be useful as a pharmaceutical composition for suppressing cancer metastasis.
Patent EP-3615008-A1 (EP)
Inventor: AMEDIO JOHN
IPC: C07D473/34
Filed: 2018-04-24
Abstract: Provided herein are novel and improved oral formulations for Hsp90 inhibitors.
Patent EP-3703518-A1 (EP)
Inventor: DICKENS COLIN
IPC: A24B15/16
Filed: 2018-10-31
Abstract: There is provided an aerosolisable formulation comprising (i) water in an amount of at least 50 wt.% based on the aerosolisable formulation; (ii) one or more flavours; and (iii) one or more cyclodextrins.
Patent EP-3707221-A1 (EP)
Title: Compositions de fluide de forage et procédés associés
Inventor: ALBAHRANI HUSSAIN
IPC: C09K8/575
Filed: 2018-10-31
Abstract: La présente demande concerne une boue de forage contenant un fluide de base aqueux ; un matériau particulaire solide ; un agent chélatant hygroscopique ; éventuellement un formiate alcalin ; et éventuellement un ingrédient supplémentaire tel qu'un agent antimousse, un modificateur de viscosité, un stabilisant, de la soude ou du bicarbonate de sodium. Des procédés de préparation de la boue de forage selon l'invention et des procédés d'utilisation de ladite boue de forage pour forer une section de réservoir ou une section de production de formation souterraine sont en outre décrits.
Patent EP-3608654-A1 (EP)
Inventor: GAN HONG
IPC: G01R31/00
Filed: 2018-05-22
Abstract: Embodiments of the present invention disclose a dustproof test device, including a test box and a dust supply apparatus, where the test box includes a sample cabin, the dust supply apparatus is connected to the test box through a dust tube, and the dust supply apparatus is configured to transport dust into the sample cabin under the action of compressed air. The embodiments of the present invention further provide a dustproof test method. According to the dustproof test device and method provided in the embodiments of the present invention, a reliability growth test can be performed on an electronic product.
Patent EP-3630221-A1 (EP)
Title: Absolute blood volume estimation device and method
Inventor: CHAIT YOSSI
IPC: A61M1/28
Filed: 2018-06-01
Abstract: Absolute blood volume in dialysis patients is a useful patient attribute to know for dialysis treatment, diagnosis, adjustments, etc. In some cases, it is difficult or impossible to directly determine absolute blood volume. Estimating absolute blood volume may be used to overcome the inability to directly determine the absolute blood volume. Estimating absolute blood volume may include obtaining a series of measurements of hemoconcentration of a patient over a time period, and estimating parameters for a physiological model based on the series of measurements. The absolute blood volume of the patient may be determined using the physiological model.
Patent EP-3625707-A1 (EP)
Inventor: BERNHARDY KYLE
IPC: G06F17/30
Filed: 2018-05-31
Abstract: This disclosure describes systems, methods, and apparatus for creating or updating a table in a fully-indexed hierarchical database for storing both structured and unstructured data, where the database structure rather than separate index files provides indexing. The database includes a hierarchy of nodes where the lowest nodes represent raw data and hard links to the raw data. Data records in a table, write request, update request, etc. can be exploded into attributes and values for those attributes, and then each value is stored in a separate file at the lowest nodes of the hierarchy.